TransCode Therapeutics, Inc. Price & Performance (RNAZ)

NKGen Biotech is presenting its innovative NK cell therapy, troculeucel, at the Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The therapy, designed for neurodegenerative diseases, has earned FDA Fast Track status for moderate Alzheimer’s and a new investigational drug designation for Parkinson’s Disease, highlighting its clinical promise.1

TransCode Therapeutics has progressed to the third cohort in its Phase 1 trial for TTX-MC138, a cancer therapy, after favorable safety reviews. Despite this, the biotech firm faces challenges, with its stock hitting a 52-week low of $0.69, reflecting a sharp 96.75% annual decline amidst investor concerns.2

TransCode Therapeutics has received approval to expand its Phase I/II trial for TTX-MC138 to a fourth cohort, increasing doses by 50%. Favorable safety data from earlier cohorts support this move, although efficacy signals are still awaited. This development underscores the ongoing refinement of its RNA-targeted cancer treatment.3